No headlines found.
COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
PRNewswire (Thu, 26-Mar 8:30 AM ET)
CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement
PRNewswire (Tue, 24-Mar 4:01 PM ET)
CollPlant Biotechnologies Launches Redesigned Corporate Website
PRNewswire (Wed, 18-Mar 9:00 AM ET)
COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS
PRNewswire (Wed, 11-Mar 8:00 AM ET)
PRNewswire (Thu, 26-Feb 8:00 AM ET)
CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex
PRNewswire (Mon, 23-Feb 7:00 AM ET)
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
PRNewswire (Tue, 17-Feb 7:00 AM ET)
COLLPLANT BIOTECHNOLOGIES ANNOUNCES $2.0 MILLION REGISTERED DIRECT OFFERING
PRNewswire (Thu, 5-Feb 8:00 AM ET)
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives key revenue, Canada, Europe and Other, and Israel.
Collplant Biotechnologies Ltd. - trades on the NASDAQ stock market under the symbol CLGN.
As of April 1, 2026, CLGN stock price was flat at $0.53 with 17,532 million shares trading.
CLGN has a beta of 0.13, meaning it tends to be less sensitive to market movements. CLGN has a correlation of 0.00 to the broad based SPY ETF.
CLGN has a market cap of $6.84 million. This is considered a Sub-Micro Cap stock.
Last quarter Collplant Biotechnologies Ltd. - reported $60,000 in Revenue and -$.25 earnings per share. This fell short of revenue expectation by $-7 million and missed earnings estimates by -$.06.
In the last 3 years, CLGN traded as high as $8.90 and as low as $.50.
CLGN has underperformed the market in the last year with a price return of -79.3% while the SPY ETF gained +18.5%. CLGN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -61.9% and -11.0%, respectively, while the SPY returned -3.6% and -2.1%, respectively.
CLGN support price is $.48 and resistance is $.59 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLGN shares will trade within this expected range on the day.